title: [Chemotherapy of Borrmann type 4 gastric cancer].
abstract: In brief, the clinical course of patients with Borrmann type 4 gastric cancer is characterized by its marked tendency for peritoneal metastasis (P-factor). This paper dealt with the treatment of Borrmann type 4 gastric cancer from the viewpoint of the disease P-factor, and included the following topics; UFTM chemotherapy, pharmacokinetics of mitomycin C (i.v. vs i.p. use), case presentation, Port-A-catheter (implantable drug delivery system), suppression of collagen biosynthesis, prevention of the adverse effects of mitomycin C, neochemotherapy, and autopsy findings.
mesh_terms: D002293:Adenocarcinoma, Scirrhous / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002404:Catheterization; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D010396:Penicillamine / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil; D010396:Penicillamine